OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Editorial Board	111
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	111
Editorial Board	73
Editorial Board	72
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	60
Genetics of pubertal timing	54
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	54
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	52
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	50
Menopausal hormone therapy for the management of osteoporosis	47
Regulation of bone mass: A splendid Orchestra	43
Coronavirus disease 2019 and vitamin D	43
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	42
Editorial Board	40
Sexual health and contraception in the menopause journey	38
The role of androgens in transgender medicine	38
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	38
Prenatal exposure to phthalate esters and its impact on child development	37
Immune checkpoint inhibitor-related thyroid dysfunction	37
Editorial Board	36
Haematological actions of androgens	33
Cardiometabolic outcomes of early onset hypogonadism in males	32
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	32
Remnant lipoprotein particles and cardiovascular disease risk	31
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	30

Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	29
Non-oestrogen-based and complementary therapies for menopause	27
Medullary thyroid cancer - An update	26
The effect of osteoporosis treatment on bone mass	26
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	26
Editorial Board	25
Type 1 diabetes related to immune checkpoint inhibitors	25
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	25
Radioiodine therapy in the different stages of differentiated thyroid cancer	24
Endocrine-disrupting chemicals and behaviour: A high risk to take?	24
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	24
Metabolic complications and their mechanisms in patients with craniopharyngioma	24
Hormone therapy for menopause and premature ovarian insufficiency	23
Immune checkpoint inhibitor-related hypophysitis	23
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	23
Safety of androgen therapy in men with prostate cancer	22
Approach to patients with elevated low-density lipoprotein cholesterol levels	22
Editorial Board	22
Pathophysiology of thyroid-associated orbitopathy	22
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	21
The role of hormone therapy in urogenital health after menopause	21
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	21
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	21
Localization in primary hyperparathyroidism	20
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	20
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	20
History of androgens and androgen action	20
Editorial Board	19
Editorial Board	19
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	18
Genetics of anti-Müllerian hormone and its signaling pathway	18
Genotype-phenotype correlations in Graves’ disease	18
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Endocrine disrupting chemicals and bone	18
Hormone replacement in disorders of sex development, and long-term effects	17
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	17
Preface	17
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	17
Exercise and physical activity in individuals at risk of fracture	16
Care quality improvement in differences of sex development	16
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	15
Editorial Board	15
COVID-induced thyroid autoimmunity	15
Anaplastic thyroid cancer: An update	15
Chemokines in thyroid autoimmunity	15
Covid-19 and endocrinology	14
Paraneoplastic autoimmune hypophysitis: An emerging concept	14
Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	14
Preface	14
Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	14

The epidemiology of disorders of sex development	14
Editorial Board	13
Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess	13
Endocrine abnormality in paraneoplastic syndrome	13
The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	13
How best to monitor the specific side effects of medical treatments of Cushing’s disease	12
Exposure to endocrine-disrupting compounds such as phthalates and bisphenol A is associated with an increased risk for obesity	12
Menopausal hormone therapy in women with medical conditions	11
Surgical treatment of thyroid cancer: Established and novel approaches	11
SARS-CoV-2 infection and its effects on the endocrine system	11
Quality of life in thyroid cancer	11
Regulation of bone mass in endocrine diseases including diabetes	10
Real-world value of cabergoline in the treatment of acromegaly	10
Role of sex steroids hormones in the regulation of bone metabolism in men: Evidence from clinical studies	10
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	10
Current medical treatment and perspective in gonadotroph tumors	10
Adolescent primary hyperparathyroidism	10
Management of patients with statin intolerance	9
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	9
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	9
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	9
Editorial Board	9
Androgen-based therapies in women	9
Long-term thionamide antithyroid treatment of Graves' disease	9
COVID-19 vaccination and thyroiditis	9
Genetics of 46,XY gonadal dysgenesis	9
Androgens part 2: Emerging areas	8
Inherited fibroblast growth factor 23 excess	8
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	8
Burosumab: Current status and future prospects	8
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	8
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model	8
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	8
Phthalates, ovarian function and fertility in adulthood	8
Pituitary and SARS CoV-2: An unremitting conundrum	8
Outcomes of recombinant growth hormone therapy in the traumatic brain injury population: A scoping review	7
Associations of prenatal exposure to phthalates and one phthalate substitute with anthropometric measures in early life: Results from the German LIFE Child cohort study	7
Novel androgen therapies including selective androgen receptor modulators	7
Vitamin D deficiency or resistance and hypophosphatemia	7
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	7
Androgen therapy for women after menopause	6
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	6
Heritable hyperparathyroidism: Genetic insights and clinical implications	6
Traumatic brain injury and hypopituitarism	6
Tumor-induced osteomalacia: An overview	6
Innovative therapeutics in acromegaly	5
Pituitary dysfunction due to sports injuries	5
Morbidity and mortality in men: Role of androgens	5
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	5
Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis	5
Broader impact and outcome of human NR5A1/SF1 variants	5
Genetics of ovarian insufficiency and defects of folliculogenesis	5
Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?	5
Management of non-hepatic distant metastases in neuroendocrine neoplasms	5
New advances in menopause symptom management	5
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review	4
Androgens, sports, and detection strategies for anabolic drug use	4
Editorial Board	4
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	4
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective	4
Primary hyperparathyroidism	4
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	4
Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: How articles of daily use influence the development of our children	4
Thyroid hormone system disrupting chemicals	4
In utero exposure to phthalates and reproductive toxicity in rodents	4
Editorial Board	4
Developments in interventional management of hepatic metastases from neuroendocrine tumours	4
The pathophysiology of hypophosphatemia	4